Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis

References

• Aliyuda F, Moschetta M, Ghose A, Sofia Rallis K, Sheriff M, Sanchez E, et al. Advances in ovarian cancer treatment beyond PARP Inhibitors. Curr Cancer Drug Targets. 2023; 23(6):433–446. doi:10.2174/1568009623666230209121732.
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024; 200:113580. doi:10.1016/j.ejca.2024.113580.
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Gutierrez ME, Parchment RE, Phillips LR, Ji J, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705–2711. doi:10.1200/JCO.2008.19.7681.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020; 38(1):181–193. doi:10.1007/s10637-019-00867-4.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–892. doi:10.1016/S1470-2045(13)70240-7.
   PubMed Web of Science ®Google Scholar
• Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, et al. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol. 2019; 84(6):1289–1301. doi:10.1007/s00280-019-03960-w.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4.
   PubMedGoogle Scholar
• Chabot P, Hsia TC, Ryu JS, Gorbunova V, Belda-Iniesta C, Ball D, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol. 2017; 131(1):105–115. doi:10.1007/s11060-016-2275-x.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019; 381(25):2403–2415. doi:10.1056/NEJMoa1909707.
   PubMed Web of Science ®Google Scholar
• Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, et al. A phase 2 randomised study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer. Br J Cancer. 2019; 120(2):183–189. doi:10.1038/s41416-018-0343-z.
   PubMed Web of Science ®Google Scholar
• Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015; 21(7):1574–1582. doi:10.1158/1078-0432.CCR-14-2565.
   PubMed Web of Science ®Google Scholar
• Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016; 34(3):355–363. doi:10.1007/s10637-016-0335-x.
   PubMed Web of Science ®Google Scholar
• Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19(4):497–509. doi:10.1016/S1470-2045(18)30111-6.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, et al. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015; 26(10):2173–2179. doi:10.1093/annonc/mdv308.
   PubMed Web of Science ®Google Scholar
• Munasinghe W, Stodtmann S, Tolcher A, Calvo E, Gordon M, Jalving M, et al. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemother Pharmacol. 2016; 78(5):1003–1011. doi:10.1007/s00280-016-3156-x.
   PubMed Web of Science ®Google Scholar
• O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020; 38(13):1378–1388. doi:10.1200/JCO.19.02931.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL, 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222–229. doi:10.1200/JCO.18.00264.
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018; 36(23):2386–2394. doi:10.1200/JCO.2018.77.7672.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, et al. Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer. Clin Cancer Res. 2017; 23(8):1937–1944. doi:10.1158/1078-0432.CCR-15-3069.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016; 375(1):23–34. doi:10.1056/NEJMoa1513749.
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(10):1269–1282. doi:10.1016/S1470-2045(20)30447-2.
   PubMed Web of Science ®Google Scholar
• Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023; 24(2):162–174. doi:10.1016/S1470-2045(22)00739-2.
   PubMed Web of Science ®Google Scholar
• Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, et al. Veliparib plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Clin Lung Cancer. 2022; 23(3):214–225. doi:10.1016/j.cllc.2022.01.005.
   PubMed Web of Science ®Google Scholar
• Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naïve extensive-stage small cell lung cancer: a phase 2 randomized study. Clin Cancer Res. 2021; 27(14):3884–3895. doi:10.1158/1078-0432.CCR-20-4259.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, et al. Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study. J Clin Oncol. 2021; 39(32):3633–3644. doi:10.1200/JCO.20.03318.
   PubMed Web of Science ®Google Scholar
• Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, et al. A dose-finding study followed by a phase II randomized, placebo-controlled trial of chemoradiotherapy with or without veliparib in stage III non-small-cell lung cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021; 22(4):313–323.e1. doi:10.1016/j.cllc.2021.02.009.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, et al. Randomized phase II study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513. Clin Cancer Res. 2021; 27(23):6314–6322. doi:10.1158/1078-0432.CCR-21-1789.
   PubMed Web of Science ®Google Scholar
• Sim HW, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, et al. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol. 2021; 23(10):1736–1749. doi:10.1093/neuonc/noab111.
   PubMed Web of Science ®Google Scholar
• Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021; 22(18):9783. doi:10.3390/ijms22189783.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019; 20(1):e15–e28. doi:10.1016/S1470-2045(18)30786-1.
   PubMed Web of Science ®Google Scholar
• Cai Z, Liu C, Chang C, Shen C, Yin Y, Yin X, et al. Comparative safety and tolerability of approved PARP inhibitors in cancer: a systematic review and network meta-analysis. Pharmacol Res. 2021; 172:105808. doi:10.1016/j.phrs.2021.105808.
   PubMed Web of Science ®Google Scholar
• Sun W, Li J, Zhang Z, Su X. Gastrointestinal events with PARP inhibitors in cancer patients: a meta-analysis of phase II/III randomized controlled trials. J Clin Pharm Ther. 2021; 46(2):241–255. doi:10.1111/jcpt.13300.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia Pac J Clin Oncol. 2016;12(4):323–331. doi:10.1111/ajco.12636.
   PubMed Web of Science ®Google Scholar